Immune Checkpoint Inhibitor Nephrotoxicity: What do we know and what should we do?

The immune-checkpoint inhibitors have dramatically improved cancer therapy for many patients. These humanized monoclonal antibodies against various immune-checkpoints (receptors and ligands) effectively treat a number of malignancies by unleashing the immune system to destroy cancer cells. These drugs are not excreted by the kidneys or liver, have a long half-life, and undergo receptor-mediated clearance. While these agents have greatly improved the prognosis of many cancers, immune-related end organ injury is a complication that has come to light in clinical practice.
Source: Kidney International - Category: Urology & Nephrology Authors: Tags: Review Source Type: research